Clinical Trials

254 enrolled

Carcinoma, Renal Cell

NCT07227415 2026-05-22

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

224 enrolled

DermatologicHead & NeckThoracic

Clear-cell metastatic renal cell carcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Neoplasms, Neoplasm Metastasis

NCT03645928 2026-05-15

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Terminated

225 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06946797 2026-05-14

CheckMate-1533

Phase 2 Active not recruiting

76 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07291076 2026-05-14

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

129 enrolled

Phase 1/2 Active not recruiting

Carcinoma, Hepatocellular

NCT05933265 2026-05-04

Study of LP-184 in Patients With Advanced Solid Tumors

64 enrolled

Breast

Neoplasm Metastasis, Neoplasms, Triple Negative Breast Neoplasms

NCT07563738 2026-05-04

TEADCO

GastrointestinalOther solid neoplasmThoracic

229 enrolled

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

NCT05536141 2026-05-01

ARC-20

Phase 1 Recruiting

362 enrolled

Other solid neoplasmThoracic

Erythrocytosis, Familial, 4, Carcinoma, Renal Cell, Kidney Neoplasms

NCT06097728 2026-04-28

eVOLVE-Meso

Phase 3 Recruiting

825 enrolled

Mesothelioma, Malignant, Mesothelioma

NCT06624644 2026-04-22

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

135 enrolled

Melanoma

NCT01604889 2026-04-21

A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma

Phase 1/2 Terminated

50 enrolled

Melanoma, Neoplasms, Skin Neoplasms

NCT06743126 2026-04-21

SUPRAME

Phase 3 Recruiting

360 enrolled

Melanoma, Cutaneous Malignant

NCT07227012 2026-04-20

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

138 enrolled

Carcinoma, Hepatocellular, Liver Neoplasms

NCT07526961 2026-04-14

Real-World Outcomes of First-Line Nivolumab + Ipilimumab With Chemotherapy in Non-Small Cell Lung Cancer in Poland

Completed

240 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06362369 2026-04-13

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT03459222 2026-04-06

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

Phase 1/2 Completed

229 enrolled 21 charts

Advanced Cancer

NCT04039607 2026-04-06

CheckMate 9DW

Phase 3 Active not recruiting

732 enrolled 1 FDA

Carcinoma, Hepatocellular

NCT05533697 2026-04-03

Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors

361 enrolled

Neoplasm Metastasis, Neoplasms, Recurrence

NCT04665206 2026-04-02

Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

Other solid neoplasmThoracic

434 enrolled

Mesothelioma

NCT06581406 2026-04-02

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Phase 1 Active not recruiting

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT03860272 2026-03-30

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

499 enrolled

GastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fibrolamellar hepatocellular carcinoma, Carcinoma, Non-Small-Cell Lung, Hemangiosarcoma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms

NCT03070392 2026-03-17

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Phase 2 Completed

378 enrolled 15 charts 1 FDA

Uveal Melanoma, Melanoma

NCT07176650 2026-03-16

Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma

Phase 1 Recruiting

246 enrolled

Phase 3 Active not recruiting

Carcinoma, Hepatocellular

NCT07000149 2026-03-10

eVOLVE-RCC02

1,116 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT05926960 2026-03-09

PORTSIDE

Phase 2 Terminated

38 enrolled

Phase 3 Active not recruiting

Melanoma, Skin Neoplasms

NCT03036098 2026-03-06

CheckMate901

1,314 enrolled 23 charts 1 FDA

Urothelial Cancer

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis